Medical Xpress February 25, 2025
Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.
Researchers from the University of Oxford have conducted a comprehensive overview of the potential benefits or harms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (better known as Ozempic/Wegovy) in various mental health conditions. This important study explores the mechanisms and possible clinical uses of these drugs, commonly used for diabetes and obesity, on cognitive and psychiatric conditions.
The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs in conditions such as dementia, substance use disorders, psychotic disorders, mood...
Today's Sponsors
Today's Sponsor